WJNSWorld Journal of Neuroscience2162-2000Scientific Research Publishing10.4236/wjns.2020.102013WJNS-100265ArticlesBiomedical&Life Sciences Immunotherapy for the Post-Infectious Sequela of SARS-CoV-2 Infection DavidS. Younger1*School of Medicine, City University of New York, New York, NY, USA0904202010021171207, May 202015, May 2020 18, May 2020© Copyright 2014 by authors and Scientific Research Publishing Inc. 2014This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/

The SARS-CoV-2 2019 pandemic is creating challenges to the management of post-infectious autoimmunity in childhood and adult Covid-19 cases due to its high case fatality. Nearly all of the agents envisioned to treat Covid-19 illness, including the newly recognized pediatric multi-system inflammatory syndrome, impact post-infectious mechanisms in keeping with the multiplier effect of infection, immunity and inflammation, known as I-Cubed (I 3 ).

SARS-CoV-2 Covid-19 Intravenous Immune Globulin IVIg Pediatric Multi-System Inflammatory SyndromeConflicts of Interest

The author declares no conflicts of interest regarding the publication of this paper.

Cite this paper

Younger, D.S. (2020) Immunotherapy for the Post-Infectious Sequela of SARS-CoV-2 Infection. World Journal of Neuroscience, 10, 117-120. https://doi.org/10.4236/wjns.2020.102013

ReferencesGuo, X.J. and Thomas, P.G. (2017) New Fronts Emerge in the Influenza Cytokine Storm. Seminars in Immunopathology, 39, 541-550. https://doi.org/10.1007/s00281-017-0636-yGuan, W.J., Ni, Z.Y., Hu, Y., et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. The New England Journal of Medicine, 382, 1708-1720. https://doi.org/10.1056/NEJMoa2002032Younger, D.S. (2016) I-Cubed (Infection, Immunity, and Inflammation) and the Human Microbiome. Neurologic Clinics, 34, 863-874. https://doi.org/10.1016/j.ncl.2016.05.006Biot, C., Daher, W., Chavain, N., et al. (2006) Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities. Journal of Medicinal Chemistry, 49, 2845-2849. https://doi.org/10.1021/jm0601856Gautret, P., Lagier, J.C., Parola, P., et al. (2020) Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents, 2020, Article ID: 105949.Geleris, J., Sun, Y., Platt, J., et al. (2020) Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2012410Grein, J., Ohmagari, N., Shin, D., et al. (2020) Compassionate Use of Remdesivir for Patients with Severe Covid-19. The New England Journal of Medicine.Shen, C., Wang, Z., Zhao, F., et al. (2020) Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma. JAMA, 323, 1582-1589. https://doi.org/10.1001/jama.2020.4783Cao, W., Liu, X., Bai, T., et al. (2020) High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients with Coronavirus Disease 2019. Open Forum Infectious Diseases, 7, ofaa102. https://doi.org/10.1093/ofid/ofaa102Harahsheh, A.S., Dahdah, N., Newburger, J.W., et al. (2020) Missed or Delayed Diagnosis of Kawasaki Disease during the 2019 Novel Coronavirus Disease (COVID-19) Pandemic. The Journal of Pediatrics. https://doi.org/10.1016/j.jpeds.2020.04.052Younger, D.S. (2020) Post-Infectious Sequela of SARS-COV-2 Infection in Adults and Children: An Overview of Available Agents and Clinical Responsiveness. Arch Neurology and Neurological Disorder, 3, e102.